Molecular Templates Inc (NASDAQ:MTEM) shares traded -2.06% lower at $0.38 on Wall Street last session.
MTEM stock price is now -55.72% away from the 50-day moving average and -76.30% away from the 200-day moving average. The market capitalization of the company currently stands at $2.50M.
With the price target of $12, BofA Securities recently initiated with Buy rating for Molecular Templates Inc (NASDAQ: MTEM). On February 01, 2021, UBS recently initiated its ‘Neutral’ rating on the stock quoting a target price of $13, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, BIOTECH TARGET N V, 10% Owner sold 1,279,820 shares of the company’s stock on Nov 14 ’24. The stock was sold for $845,833 at an average price of $0.66. Upon completion of the transaction, the 10% Owner now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 02 ’24, 10% Owner BIOTECH TARGET N V bought 250,000 shares of the business’s stock. A total of $587,500 was incurred on buying the stock at an average price of $2.35. This leaves the insider owning 1,279,820 shares of the company worth $0.49 million. A total of 17.39% of the company’s stock is owned by insiders.
During the past 12 months, Molecular Templates Inc has had a low of $0.29 and a high of $5.37. As of last week, the company has a debt-to-equity ratio of 1.55, a current ratio of 1.56, and a quick ratio of 1.56. The fifty day moving average price for MTEM is $0.8736 and a two-hundred day moving average price translates $1.6193 for the stock.
The latest earnings results from Molecular Templates Inc (NASDAQ: MTEM) was released for 2024-06-30. The net profit margin was -61.35% and return on equity was -929.14% for MTEM. The company reported revenue of $0.57 million for the quarter, compared to $6.87 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -91.67 percent.
